Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute ...

A community in England is in mourning after a teenage boy, 16-year-old Harley Andrews, died just one day after being ...

The FDA approved a drug made by Kura Oncology to treat patients with a certain type of genetically altered leukemia.

The U.S. Food and Drug Administration (FDA) has approved Komzifti (ziftomenib), which is a type of treatment known as a menin ...

Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1 -mutated AML who have no satisfactory ...

Two phase 3 trials will study Kura Oncology’s ziftomenib for frontline acute myeloid leukemia, one with venetoclax and the ...

Kyowa Kirin’s big bet on Kura Oncology has paid off in short order, delivering an FDA approval for a medicine to treat a ...

4A10, a monoclonal antibody targeting interleukin-7 receptor alpha (IL-7Rα; CD127), has received fast track designation from the FDA for the treatment of patients with relapsed or refractory acute ...

The U.S. Food and Drug Administration has approved Kura Oncology's drug to treat a rare form of blood cancer that has ...

Ziftomenib is the first Menin inhibitor approved for relapsed or refractory mutant nucleophosmin 1 acute myeloid leukemia, showing promising efficacy in clinical trials. The phase 2 KOMET-001 trial ...

It’s up to Maryland to prioritize public health and prevent W.R. Grace from building a plastics incinerator in Howard County, ...

Ziftomenib (Komzifti; Kura Oncology and Kyowa Kirin), an oral, once-daily, selective menin inhibitor, has received approval from the FDA for the treatment of adult patients with relapsed or refractory ...